Carbon Ion Radiotherapy in the Management of Unusual Liposarcomas: A Case Report.


Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 29 11 2018
revised: 07 12 2018
accepted: 11 12 2018
entrez: 27 2 2019
pubmed: 26 2 2019
medline: 6 6 2019
Statut: ppublish

Résumé

Liposarcomas are the most common soft-tissue sarcomas in adulthood. Orbital and spermatic cord liposarcomas are uncommon and there is no consensus on their management. The treatment of choice is wide excision, which may be destructive and lead to unacceptable morbidity. When surgery is declined by patients and in recurrent disease, management can be challenging. We report two cases of liposarcoma treated with carbon ion radiotherapy at the National Center for Oncological Hadrontherapy (Fondazione CNAO) in Italy. A woman with orbital liposarcoma and a man with spermatic cord liposarcoma were referred to our Center and accepted for carbon ion radiotherapy. The treatment was well tolerated and late toxicities were mild. Good local control was achieved in patients. In our experience, carbon ion radiotherapy is an effective and safe option, especially in cases of tumor at high risk for local relapse, in patients with multiple local recurrences, and in patients who refuse destructive surgery.

Sections du résumé

BACKGROUND BACKGROUND
Liposarcomas are the most common soft-tissue sarcomas in adulthood. Orbital and spermatic cord liposarcomas are uncommon and there is no consensus on their management. The treatment of choice is wide excision, which may be destructive and lead to unacceptable morbidity. When surgery is declined by patients and in recurrent disease, management can be challenging. We report two cases of liposarcoma treated with carbon ion radiotherapy at the National Center for Oncological Hadrontherapy (Fondazione CNAO) in Italy.
CASE REPORT METHODS
A woman with orbital liposarcoma and a man with spermatic cord liposarcoma were referred to our Center and accepted for carbon ion radiotherapy. The treatment was well tolerated and late toxicities were mild. Good local control was achieved in patients.
CONCLUSION CONCLUSIONS
In our experience, carbon ion radiotherapy is an effective and safe option, especially in cases of tumor at high risk for local relapse, in patients with multiple local recurrences, and in patients who refuse destructive surgery.

Identifiants

pubmed: 30804137
pii: 33/2/529
doi: 10.21873/invivo.11506
pmc: PMC6506314
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-533

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Cancer. 1994 Jul 15;74(2):697-702
pubmed: 8033050
Phys Med Biol. 2013 Jun 7;58(11):3837-47
pubmed: 23681116
Radiother Oncol. 2016 Aug;120(2):307-12
pubmed: 27394694
Orbit. 2007 Mar;26(1):43-5
pubmed: 17510871
Phys Med Biol. 1999 Jan;44(1):185-205
pubmed: 10071883
Ann Oncol. 2010 May;21(5):1106-11
pubmed: 19858086
Phys Med Biol. 2012 Nov 21;57(22):7543-54
pubmed: 23104051
Int J Ophthalmol. 2011;4(4):452-3
pubmed: 22553700
Orbit. 2003 Dec;22(4):311-6
pubmed: 14685908
Phys Med. 2015 Jun;31(4):333-51
pubmed: 25840619
Radiother Oncol. 2012 Apr;103(1):32-7
pubmed: 22321201
Can J Ophthalmol. 2007 Jun;42(3):481-3
pubmed: 17508053
Med Phys. 2015 Jan;42(1):263-75
pubmed: 25563266
Ann Surg Oncol. 2014 Oct;21(11):3557-63
pubmed: 24802908
Technol Cancer Res Treat. 2014 Aug;13(4):303-14
pubmed: 24206209
Orbit. 1999 Mar;18(1):33-36
pubmed: 12048696
Ann Diagn Pathol. 2001 Oct;5(5):255-66
pubmed: 11598853
J Craniofac Surg. 2011 May;22(3):1139-41
pubmed: 21586970
Mol Clin Oncol. 2017 Mar;6(3):438-440
pubmed: 28451429
Med Phys. 2015 Sep;42(9):5287-300
pubmed: 26328978
Phys Med Biol. 2000 Nov;45(11):3319-30
pubmed: 11098906
Int J Oral Maxillofac Surg. 2001 Apr;30(2):170-2
pubmed: 11405455

Auteurs

Viviana Vitolo (V)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Amelia Barcellini (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Piero Fossati (P)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Maria Rosaria Fiore (MR)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Barbara Vischioni (B)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Alberto Iannalfi (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Angelica Facoetti (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy angelica.facoetti@cnao.it.

Maria Bonora (M)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Sara Ronchi (S)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Emma D'Ippolito (E)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Rachele Petrucci (R)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Gisela Viselner (G)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Lorenzo Preda (L)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.

Mario Ciocca (M)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Francesca Valvo (F)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Roberto Orecchia (R)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.
European Institute of Oncology, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH